Format

Send to

Choose Destination
See comment in PubMed Commons below
Drug News Perspect. 2008 May;21(4):218-24. doi: 10.1358/dnp.2008.21.4.1213351.

Lysyl oxidase as a potential therapeutic target.

Author information

  • 1Centro de Investigacion Cardiovascular (CSIC-ICCC), Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. crodriguezs@csic-iccc.org

Abstract

Lysyl oxidase (LOX) is a copper-dependent amine oxidase that catalyzes the covalent cross-link of collagens and elastin in the extracellular environment, thereby determining the mechanical properties of extracellular matrix (ECM) and connective tissues. ECM remodeling is a common feature of diverse pathologic processes. Therefore, dysregulation of LOX could underlie the onset and progression of multiple pathologies affecting connective tissue, such as fibrotic processes, tumor progression and metastasis and neurodegenerative and cardiovascular diseases. Here we review clinical and experimental evidence that supports a role for LOX in the pathophysiology of those processes and point out LOX as a potential therapeutic target.

(c) 2008 Prous Science, S.A.U. or its licensors

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Prous Science
    Loading ...
    Write to the Help Desk